The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $23.89

Today's change+1.24 +5.47%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $23.89

Today's change+1.24 +5.47%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc Hits New 50-day High

Sarepta Therapeutics Inc closed up sharply Friday, rallying (U.S.)$1.24 or 5.47% to (U.S.)$23.89 and setting a new 50-day high. Over the last five days, shares have gained 14.53%, but are down 38.08% for the last year to date. Shares have underperformed the S&P 500 by 31.91% during the last year.

Key company metrics

  • Open(U.S.) $22.91
  • Previous close(U.S.) $22.65
  • High(U.S.) $24.48
  • Low(U.S.) $22.61
  • Bid / Ask(U.S.) $23.50 / (U.S.) $23.90
  • YTD % change-38.08%
  • Volume3,094,681
  • Average volume (10-day)2,799,480
  • Average volume (1-month)3,308,955
  • Average volume (3-month)6,197,230
  • 52-week range(U.S.) $8.00 to (U.S.) $41.97
  • Beta1.66
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.01
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-17,417.48%

Sarepta Therapeutics Inc has a net profit margin of -17,417.48%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.24%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue0100
Total other revenue--------
Total revenue0100
Gross profit--------
Total cost of revenue--------
Total operating expense60665242
Selling / general / administrative21241513
Research & development39413729
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-60-64-52-42
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-60-65-52-42
Income after tax-60-65-52-42
Income tax, total--------
Net income-60-65-52-42
Total adjustments to net income--------
Net income before extra. items-60-65-52-42
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-60-65-52-42
Inc. avail. to common incl. extra. items-60-65-52-42
Diluted net income-60-65-52-42
Dilution adjustment--------
Diluted weighted average shares46454241
Diluted EPS excluding extraordinary itemsvalue per share-1.31-1.44-1.25-1.01
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-1.31-1.44-1.25-1.01